Infinity Pharmaceuticals IncOver The Counter Market:INFIQ
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0000
- Day Range
- 52 Week Range
- Volume1,350
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INFIQ |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Infinity Pharmaceuticals Inc | 90.0 | 0.0x | --- |
Humanigen Inc | 23.8K | 0.0x | --- |
DNAPrint Genomics Inc | 640.0 | 0.0x | --- |
Rayont Inc | 25.1K | 0.0x | --- |
Adynxx Inc | 10.0 | 0.0x | --- |
Aeolus Pharmaceuticals Inc | 150.0 | 0.0x | --- |
Company Information
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
Contact Information
- Headquarters
- 1100 Massachusetts Avenue, Floor 4CAMBRIDGE, MA, United States 02138
- Phone
- 617-453-1000
- Fax
- 617-453-1001
Executives
- Chief Executive Officer
- Seth Tasker
- Lead Independent Director
- Norman Selby
- Independent Director
- David Beier
- Independent Director
- Anthony Evnin
- Independent Director
- Richard Gaynor
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $90.00 |
|---|---|
Revenue (TTM) | $2.6M |
Shares Outstanding | 90.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.30 |
EPS | $-0.46 |
Book Value | $-0.21 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,636.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
